oral β-glucan

BIOLOGICAL2 trials

Sponsors

Memorial Sloan Kettering Cancer Center

Conditions

High-risk NeuroblastomaMetastatic NeuroblastomaNeuroblastoma

Phase 1

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

CompletedNCT00911560

Memorial Sloan Kettering Cancer CenterNeuroblastoma

Start: 2009-05-27End: 2026-08-03Updated: 2026-08-05

Phase 2

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

RecruitingNCT06057948

Memorial Sloan Kettering Cancer CenterHigh-risk Neuroblastoma, Metastatic Neuroblastoma, Neuroblastoma

Start: 2023-09-21End: 2027-03-21Target: 94Updated: 2026-07-28

Related Papers

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons

Journal of Clinical Oncology2023-10-2657 citations

Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma

JAMA Oncology2022-12-2231 citations

Abstract 5218: Oral beta-glucan enhanced anti-ganglioside antibody titer after vaccination against high-risk neuroblastoma: Results of a randomized trial

Cancer Research2022-06-15

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression

Journal of Clinical Oncology2020-12-16106 citations

Abstract LB-092: Survival impact of anti-GD2 antibody response - A phase II ganglioside vaccine trial in relapsed neuroblastoma

Cancer Research2020-08-15

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.

2018-10-1616 citations

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

2014-02-11101 citations